PMID- 11385257
OWN - NLM
STAT- MEDLINE
DCOM- 20010726
LR  - 20171101
IS  - 0014-3022 (Print)
IS  - 0014-3022 (Linking)
VI  - 45
IP  - 4
DP  - 2001
TI  - Tolerability and efficacy of almotriptan in the long-term treatment of migraine.
PG  - 206-13
AB  - BACKGROUND: Almotriptan is a highly specific 5-HT(1B/1D) receptor agonist, which 
      acts selectively on blood vessels of the brain. Short-term studies have 
      demonstrated that almotriptan provides rapid, effective and reliable relief of 
      migraine attacks, while offering excellent tolerability. PURPOSE: To assess the 
      long-term tolerability and efficacy of oral almotriptan 12.5 mg administered for 
      every migraine attack over a 1-year period. METHODS: A total of 762 patients 
      treated 13,751 attacks (1-97 per patient); 61.5% of attacks were treated with one 
      12.5-mg dose, while for 38.5% of attacks, patients took a second dose within 24 
      h. RESULTS: Three hundred and ninety-one patients (51.3%) experienced a total of 
      1,617 adverse events (AEs). The majority (88.6%) of AEs were of mild-to-moderate 
      intensity, and only 28.8% of AEs were considered to be related to the study drug. 
      Only 2 patients experienced serious AEs possibly related to almotriptan, syncope 
      and chest pain; both recovered without any sequelae. Patients reported at least 1 
      AE in 11% of attacks treated. The incidence of AEs decreased during the study. 
      Only 6 (0.8%) study withdrawals were due to AEs considered to be related to 
      almotriptan. Tolerability was not compromised in patients taking 2 doses of 
      almotriptan or in those using migraine prophylactics. Patient age or sex did not 
      influence the incidence of AEs. There was no evidence of tachyphylaxis in those 
      patients completing the study. Pain relief at 2 h after the initial dose was 
      achieved in 84.2% of moderate/severe attacks. Patients were pain free at 2 h 
      after dose in 58.2% of all attacks. Older patients (> 40 years) tended to respond 
      better than younger ones (< 40 years). Efficacy was not modified by use of 
      migraine prophylactics or hormonal contraceptives. Efficacy measurements were 
      consistent on treating repeated moderate/severe migraine attacks. CONCLUSION: 
      This large, open study indicates that the new, specific 5-HT(1B/1D) agonist 
      almotriptan, at a dose of 12.5 mg, is a well tolerated and effective treatment 
      for migraine pain when used over a period of up to 1 year.
CI  - Copyright 2001 S. Karger AG, Basel
FAU - Pascual, J
AU  - Pascual J
AD  - Servicio de Neurologia, University Hospital, Santander, Spain. 
      pascualj@medi.unican.es
FAU - Falk, R
AU  - Falk R
FAU - Docekal, R
AU  - Docekal R
FAU - Prusinski, A
AU  - Prusinski A
FAU - Jelencsik, J
AU  - Jelencsik J
FAU - Cabarrocas, X
AU  - Cabarrocas X
FAU - Segarra, X
AU  - Segarra X
FAU - Luria, X
AU  - Luria X
FAU - Ferrer, P
AU  - Ferrer P
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PL  - Switzerland
TA  - Eur Neurol
JT  - European neurology
JID - 0150760
RN  - 0 (Indoles)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 0 (Tablets)
RN  - 0 (Tryptamines)
RN  - 1O4XL5SN61 (almotriptan)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Indoles/*pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Pain Measurement
MH  - Self Administration
MH  - Serotonin Receptor Agonists/*pharmacology/*therapeutic use
MH  - Tablets
MH  - *Time
MH  - Treatment Outcome
MH  - Tryptamines
EDAT- 2001/06/01 10:00
MHDA- 2001/07/28 10:01
CRDT- 2001/06/01 10:00
PHST- 2001/06/01 10:00 [pubmed]
PHST- 2001/07/28 10:01 [medline]
PHST- 2001/06/01 10:00 [entrez]
AID - 52131 [pii]
AID - 10.1159/000052131 [doi]
PST - ppublish
SO  - Eur Neurol. 2001;45(4):206-13. doi: 10.1159/000052131.